| # | Drug | Count |
|---|---|---|
| 0 | CYTARABINE | 29 |
| 1 | METHOTREXATE SODIUM | 21 |
| 2 | RITUXIMAB | 21 |
| 3 | CYCLOPHOSPHAMIDE | 20 |
| 4 | CYCLOPHOSPHAMIDE FOR INJECTION | 20 |
| 5 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 20 |
| 6 | METHOTREXATE | 20 |
| 7 | FLUDARABINE PHOSPHATE | 19 |
| 8 | VENETOCLAX | 18 |
| 9 | PREDNISOLONE | 15 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | SODIUM PHOSPHATE, DIBASIC AND SODIUM PHOSPHATE, MONOBASIC | 1 | 0.0122 |
| 1 | NATAMYCIN | 1 | 0.0024 |
| 2 | INOTUZUMAB OZOGAMICIN | 5 | 0.0017 |
| 3 | IDELALISIB | 10 | 0.0014 |
| 4 | MITOXANTRONE HYDROCHLORIDE | 8 | 0.0013 |
| 5 | ASCIMINIB | 4 | 0.0011 |
| 6 | DEXRAZOXANE FOR INJECTION | 1 | 0.0011 |
| 7 | GILTERITINIB | 4 | 0.0010 |
| 8 | THIOGUANINE | 2 | 0.0009 |
| 9 | DECITABINE | 4 | 0.0009 |
| # | Drug class | Count |
|---|---|---|
| 0 | Nucleoside Metabolic Inhibitor [EPC] | 41 |
| 1 | Corticosteroid [EPC] | 34 |
| 2 | Alkylating Drug [EPC] | 23 |
| 3 | CD20-directed Cytolytic Antibody [EPC] | 22 |
| 4 | Folate Analog Metabolic Inhibitor [EPC] | 20 |
| 5 | BCL-2 Inhibitor [EPC] | 18 |
| 6 | Kinase Inhibitor [EPC] | 16 |
| 7 | CD52-directed Cytolytic Antibody [EPC] | 9 |
| 8 | Azole Antifungal [EPC] | 8 |
| 9 | Topoisomerase Inhibitor [EPC] | 8 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Polyene Antimicrobial [EPC] | 1 | 0.0024 |
| 1 | CD22-directed Immunoconjugate [EPC] | 5 | 0.0017 |
| 2 | CD52-directed Cytolytic Antibody [EPC] | 9 | 0.0005 |
| 3 | Asparagine-specific Enzyme [EPC] | 6 | 0.0004 |
| 4 | Nitrogen Binding Agent [EPC] | 1 | 0.0004 |
| 5 | Anthracycline Topoisomerase Inhibitor [EPC] | 1 | 0.0004 |
| 6 | BCL-2 Inhibitor [EPC] | 18 | 0.0003 |
| 7 | Photoenhancer [EPC] | 1 | 0.0003 |
| 8 | Antihypoglycemic Agent [EPC] | 1 | 0.0002 |
| 9 | Provitamin D2 Compound [EPC] | 6 | 0.0002 |